Cornerstone Pharmaceuticals: Will Showcase Three Independently Developed Pipeline Results at 2026 AACR Annual Meeting

MetaMuskRat · 2026-03-18T07:14:50+00:00

People Finance News reported on March 18 that Cornerstone Pharmaceuticals announced on the Hong Kong Stock Exchange that clinical preclinical research results from three independently developed pipelines have been successfully selected for presentation in the poster session of the 2026 American Association for Cancer Research (AACR) Annual Meeting. The selected product pipelines are as follows: CS5007—EGFR/HER3 bispecific ADC, CS5008—SSTR2/DLL3 bispecific ADC, CS5006—ITGB4-targeting ADC.

MetaMuskRat

2026-03-18 07:14:50

People’s Financial News, March 18 — CStone Pharmaceuticals announced on the Hong Kong Stock Exchange that the preclinical research results of three of its independently developed pipelines have been selected for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The pipelines included are: CS5007—EGFR/HER3 bispecific ADC, CS5008—SSTR2/DLL3 bispecific ADC, and CS5006—ADC targeting ITGB4.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.